Biogen and Sage Therapeutics announce a collaboration to develop methods for the treatment of depression and movement disorders. The collaboration involves Biogen obtaining an exclusive license to develop and sell zuranolone and SAGE-324 outside the U.S., except for zuranolone sales in Japan, Taiwan and South Korea. Sage Therapeutics will receive $875 million in prepaid and $650 million in equity investments, as well as interim payments, royalties and a share in profits.